Nextbiomedical
넥스트바이오메디컬 · 389650
Health Care Medical Devices · KOSDAQ
Market cap US$254.9M (₩351.8B)
Overview
Nextbiomedical develops medical products that stop bleeding during endoscopic procedures and block blood vessels to treat tumors, using polymer and drug-delivery technology as their foundation.
Its products are used by physicians in hospitals, and it distributes them through licensing agreements with larger medical-device companies in major markets including the United States, Europe, and Japan. Listed on KOSDAQ, South Korea's tech-focused small-cap exchange, the company's commercial revenue is currently anchored by its endoscopic hemostatic powder, Nexpowder™, which is distributed globally under a licensing deal with Medtronic.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2024US$6.9M
- FY2025US$11.9M
Operating profit
- FY2024−US$2.6M
- FY2025−US$521.4K
Net income
- FY2024US$2.1M
- FY2025−US$225.4K
Key ratios (FY2025)
Why it matters
Nextbiomedical has a quality-management system partnership with Medtronic and holds domestic distribution rights through Taewong Medical for the Korean market.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?